RT Book, Section
A1 Levine, Michael
A2 Zaoutis, Lisa B.
A2 Chiang, Vincent W.
SR Print(0)
ID 1146124493
T1 Anticoagulants and Antithrombotics
T2 Comprehensive Pediatric Hospital Medicine, 2e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071829281
LK accesspediatrics.mhmedical.com/content.aspx?aid=1146124493
RD 2024/04/19
AB Under  normal  homeostatic  conditions,  the  human  body  is  at  a  constant  balance  between  clot  formation  and  destruction.  Physiologic  hemostasis  occurs  as  a  result  of  a  complex  interaction  among  platelets,  the  vascular  endothelium,  the  coagulation  cascade,  and  the  fibrinolytic  system.  Any  disorder  or  xenobiotic  that  alters  this  equilibrium  can  produce  either  excessive  thrombosis  or  hemorrhage.  Numerous  pharmacologic  agents  have  been  developed  to  prevent  thrombus  formation  by  interfering  with  platelet  adhesion  or  aggregation,  or  by  interfering  with  the  clotting  cascade.  Numerous  additional  drugs,  including  those  working  by  novel  mechanisms,  are  in  various  stages  of  development.1